Work Here?
Overview
Company Does Not Provide H1B Sponsorship
Earli is developing an early cancer-detection platform that uses programmable genetic constructs, called Synthetic Bioclassifiers, which enter cells and activate only in cancer cells. When activated, these constructs make cancer cells produce a specific protein that is released into the bloodstream, serving as a detectable biomarker for early cancer detection. The approach aims to distinguish cancerous from healthy cells by programming the system to reveal cancer signals, addressing limitations of traditional liquid biopsies. Earli plans to commercialize the diagnostic platform through partnerships with healthcare providers and pharmaceutical companies, with Accenture having invested in the company as part of its growth strategy.
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
Simplify's Take
What believers are saying
- Advanced from stealth to human lung cancer clinical trials in 2.5 years, ahead of liquid biopsy competitors.
- $104M total funding including Accenture Ventures and Alderline Group validates technology and enterprise partnership potential.
- Addressable market exceeds one million annual lives if platform achieves clinical efficacy and regulatory approval.
What critics are saying
- LNP delivery platform dependency creates supply chain vulnerability threatening clinical trial timelines and commercialization.
- Platform explicitly limited to single-cancer indications, restricting total addressable market versus pan-cancer competitors.
- Lung cancer clinical trial failure would invalidate core technology thesis and eliminate near-term revenue pathways.
What makes Earli, Inc. unique
- Synthetic biomarkers force cancer cells to autonomously produce detectable signals, overcoming early-stage tumor invisibility.
- AI-designed genetic switches enable dual-application revenue: diagnostics and therapeutic immune-oncology drug production.
- Platform technology detects cancer at Stages 1-2 via non-invasive blood samples and PET scans.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$59.5M
Above
Industry Average
Funded Over
2 Rounds
Andreessen Horowitz
Menlo VenturesIndustry standards
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 0%Earli, a startup founded by Cyriac Roeding, Dr. David Suhy, and the late Dr. Sanjiv Sam Gambhir, has raised $60 million to advance its cutting-edge cancer detection and treatment technology. The company engineers synthetic biomarkers within cancer cells, enabling earlier and more accurate detection and treatment. Following six years of research, Earli is preparing for human clinical trials, starting with lung cancer, and aims to expand its platform to other cancer types.
GLIN Impact Capital 有限責任事業組合のプレスリリース（2024年10月31日 12時10分）GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資
Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company.
Earli, the company pioneering a new approach to cancer diagnostics by forcing cancer cells to produce synthetic biomarkers, announced today that Maggie Louie accepted the roll of Vice President of Biology.
When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples.
Earli, Inc. is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
Earli, Inc. is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today